U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06867562) titled 'Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer' on March 05.
Brief Summary: This is a phase-3, open-label, multicenter, two-arm treatment study to evaluate the efficacy and safety of weekly Paclitaxel Lipid Suspension compared with weekly conventional paclitaxel in participants with platinum-resistant/refractory recurrent high-grade serous epithelial ovarian cancer.
Paclitaxel Lipid Suspension or conventional paclitaxel will be administered intravenously at a dose level of 80 mg/m2 on Day 1, Day 8 and Day 15 of each 28 days cycle.
The primary objective is to establish the non-inferiori...